Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Sees Payoff In China By Boning Up On Tax And Patent Law

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - Adept management of tax, patent and government relations issues particular to China can help Western pharmaceutical companies reap the benefits of working in the vast, developing market while avoiding pitfalls

You may also be interested in...

China Expanding Anti-Corruption Drive Across Health Sector

BEIJING - China's ongoing battle to curtail corruption was the topic of PharmAsia News' Aug. 27 audioconference, "Anti-Bribery Compliance in China - Avoiding the Pitfalls."

Insider Analysis From Jones Day: What Does the 3rd Amendment to China’s Patent Law Mean to Pharmaceutical Companies?

Accelovance’s Stephen Trevisan And Robert deGroof On China’s Clinical Research Landscape: An Interview With PharmAsia News (Part 2 of 2)  

[Editor's Note: This is part two of a two-part interview. Part one appeared in PharmAsia News, May 15, 2008.]

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts